<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00100048</url>
  </required_header>
  <id_info>
    <org_study_id>0518-004</org_study_id>
    <secondary_id>2004_096</secondary_id>
    <nct_id>NCT00100048</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED)</brief_title>
  <official_title>Multicenter, Double-Blind, Randomized, Dose Ranging Study to Compare the Safety and Activity of MK0518 Plus Tenofovir and Lamivudine (3TC) Versus Efavirenz Plus Tenofovir and Lamivudine (3TC) in ART-Naive, HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study that will investigate the safety and efficacy of an investigational drug in
      Human immunodeficiency virus (HIV) infected patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants who completed 48 weeks of the original 48-week double-blind study were invited
      to continue in two extensions: MK0518-004-10 (NCT00100048), which extended the study to 144
      weeks, and MK0518-004-20 (NCT00100048), which extended the study to 240 weeks. Participants
      who had been randomized to MK0518 in the base study continued at 400 mg MK0518 twice daily.

      Participants randomized to efavirenz in the base study continued to receive efavirenz at the
      dosage given in the base study. The doses of open label tenofovir and lamivudine continued
      unchanged.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Plasma Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) on Day 10 (Cohort I)</measure>
    <time_frame>Baseline and Day 10</time_frame>
    <description>Mean change from baseline on Day 10 in plasma Human Immunodeficiency Virus (HIV) Ribonucleic acid (RNA) (copies/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Clinical Adverse Experiences (CAEs) and Number of Patients With Serious CAEs at Day 10 (Cohort I)</measure>
    <time_frame>10 days</time_frame>
    <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.
Serious CAEs are any AEs occurring at any dose that; Results
in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or
prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an
overdose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 24 (Cohort II)</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Clinical Adverse Experiences (CAEs)</measure>
    <time_frame>48 weeks</time_frame>
    <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Serious CAEs (Cohort I and II Combined)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients With Serious CAEs and Non-serious CAEs at Week 144</measure>
    <time_frame>144 Weeks</time_frame>
    <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product
An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinical Adverse Experiences (AEs)and Serious Adverse Experiences (SAEs)</measure>
    <time_frame>Week 240</time_frame>
    <description>An AE was defined as any unfavorable &amp; unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to its use. Any worsening of a preexisting condition which was temporally associated with the use of the study drug, was also an AE.
A SAE was any AE that resulted in death, was life threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was cancer, or was an overdose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With HIV RNA (Human Immunodeficiency Virus Ribonucleic Acid) Levels Below 50 Copies/mL at Week 240</measure>
    <time_frame>Week 240</time_frame>
    <description>HIV RNA levels were determined by AMPLICOR HIV-1 Monitor™ UltraSensitive Assay.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV RNA Levels Below 50 Copies/mL at Week 24 (Cohort II)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma HIV RNA at Week 24 (Cohort II)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Mean change from baseline at Week 24 in plasma HIV RNA (copies/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Count at Week 24 (Cohort II)</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Mean change from baseline at Week 24 in CD4 Cell Count (cells/mm3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With HIV RNA Level Below 50 Copies/mL and HIV RNA Level Below 400 Copies/mL at Week 96</measure>
    <time_frame>96 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma HIV RNA at Week 96</measure>
    <time_frame>Baseline and Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 Cell Count at Week 96</measure>
    <time_frame>Baseline and Week 96</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 240</measure>
    <time_frame>Week 240</time_frame>
    <description>HIV RNA levels were determined by AMPLICOR HIV-1 Monitor™ Standard Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma HIV RNA at Week 240</measure>
    <time_frame>Baseline and Week 240</time_frame>
    <description>HIV RNA levels were determined by AMPLICOR HIV-1 Monitor™ Standard Assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4 (T-helper) Cell Count at Week 240</measure>
    <time_frame>Baseline and Week 240</time_frame>
    <description>Change in number of CD4 cells/mm^3 from baseline to Week 240.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 48</measure>
    <time_frame>48 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Drug-related CAEs</measure>
    <time_frame>48 weeks</time_frame>
    <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Serious Drug-related CAEs</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose. Drug-related are as assessed by an investigator who is a qualified physician according to his/her best clinical judgment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients That Discontinued With CAEs</measure>
    <time_frame>48 Weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Laboratory Adverse Experiences (LAEs)</measure>
    <time_frame>48 Weeks</time_frame>
    <description>A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Serious LAEs</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Drug-related LAEs</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients With Serious Drug-related LAEs</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Patients That Discontinued With LAEs</measure>
    <time_frame>48 Weeks</time_frame>
  </other_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">206</enrollment>
  <condition>HIV Infections</condition>
  <condition>Acquired Immunodeficiency Syndrome</condition>
  <arm_group>
    <arm_group_label>600 mg monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0518 600 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0518 400 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0518 200 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0518 100 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo monotherapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to MK0518 twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600 mg combo therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0518 600 mg + tenofovir + lamivudine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg combo therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0518 400 mg + tenofovir + lamivudine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg combo therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0518 200 mg + tenofovir + lamivudine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg combo therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0518 100 mg + tenofovir + lamivudine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EFV combo therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>efavirenz + tenofovir + lamivudine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: MK0518 monotherapy</intervention_name>
    <description>MK0518 twice daily for 10 days</description>
    <arm_group_label>600 mg monotherapy</arm_group_label>
    <arm_group_label>400 mg monotherapy</arm_group_label>
    <arm_group_label>200 mg monotherapy</arm_group_label>
    <arm_group_label>100 mg monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: MK0518 combination therapy</intervention_name>
    <description>MK0518 twice daily for 48 weeks</description>
    <arm_group_label>600 mg combo therapy</arm_group_label>
    <arm_group_label>400 mg combo therapy</arm_group_label>
    <arm_group_label>200 mg combo therapy</arm_group_label>
    <arm_group_label>100 mg combo therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: efavirenz</intervention_name>
    <description>efavirenz 600 mg every night at bedtime for 48 weeks</description>
    <arm_group_label>EFV combo therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: tenofovir</intervention_name>
    <description>tenofovir 300 mg daily for 48 weeks</description>
    <arm_group_label>600 mg combo therapy</arm_group_label>
    <arm_group_label>400 mg combo therapy</arm_group_label>
    <arm_group_label>200 mg combo therapy</arm_group_label>
    <arm_group_label>100 mg combo therapy</arm_group_label>
    <arm_group_label>EFV combo therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: lamivudine</intervention_name>
    <description>lamivudine 300 mg daily for 48 weeks</description>
    <arm_group_label>600 mg combo therapy</arm_group_label>
    <arm_group_label>400 mg combo therapy</arm_group_label>
    <arm_group_label>200 mg combo therapy</arm_group_label>
    <arm_group_label>100 mg combo therapy</arm_group_label>
    <arm_group_label>EFV combo therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo monotherapy</intervention_name>
    <description>Placebo to MK0518 twice daily</description>
    <arm_group_label>placebo monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient must be HIV positive who must have received less than 7 days total of any
             antiretroviral therapy (HIV related therapy)

        Extension Studies:

          -  First extension: Patient completed the 48-week base study

          -  Second extension: Patient completed the first 144-week extension study

        Exclusion Criteria:

          -  Less than 18 years of age

          -  Individuals who currently do not test positive for HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Peru</country>
    <country>Puerto Rico</country>
    <country>Thailand</country>
    <country>United States</country>
  </removed_countries>
  <reference>
    <citation>Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L, Zhao J, Teppler H. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):509-15. Erratum in: J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):492.</citation>
    <PMID>17133211</PMID>
  </reference>
  <reference>
    <citation>Murray JM, Emery S, Kelleher AD, Law M, Chen J, Hazuda DJ, Nguyen BY, Teppler H, Cooper DA. Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase. AIDS. 2007 Nov 12;21(17):2315-21.</citation>
    <PMID>18090280</PMID>
  </reference>
  <reference>
    <citation>Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Gilde LR, Wan H, Miller MD, Wenning LA, Teppler H; Protocol 004 Part II Study Team. Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007 Oct 1;46(2):125-33.</citation>
    <PMID>17721395</PMID>
  </reference>
  <reference>
    <citation>Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, Prada G, Morales-Ramirez JO, Crumpacker CS, Isaacs RD, Campbell H, Strohmaier KM, Wan H, Danovich RM, Teppler H; Protocol 004 Part II Study Team. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):350-6. doi: 10.1097/QAI.0b013e3181b064b0.</citation>
    <PMID>19648823</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2004</study_first_submitted>
  <study_first_submitted_qc>December 22, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2004</study_first_posted>
  <results_first_submitted>January 21, 2010</results_first_submitted>
  <results_first_submitted_qc>March 25, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 29, 2010</results_first_posted>
  <last_update_submitted>September 4, 2015</last_update_submitted>
  <last_update_submitted_qc>September 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Primary therapy period:
For Part I (10 day monotherapy): 24-Jan-2005 to 04-May-2005
Part II (Dose Ranging): 14-Jun-2005 to 04-Oct-2006 (48 weeks); 14-Jun-2005 to 12-Jul-2010 (240 weeks)
Multicenter (29) in the United States (14) and Ex-US (15)</recruitment_details>
      <pre_assignment_details>Patients with Human Immunodeficiency Virus (HIV) Ribonucleic acid (RNA) of at least 5000 copies/mL and cluster of differentiation 4 (CD4) cell counts of at least 100 cells/mm3. All patients must have met laboratory criteria.
206 enrolled; 5 from Cohort I did not continue to the combination phase. Therefore 201 entered the combination phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MK0518 100 mg b.i.d.</title>
          <description>Cohort I-Monotherapy Phase
MK0518 100 mg twice daily (b.i.d.)
Cohort II Combined-Combination Therapy Phase
MK0518 100 mg + tenofovir + lamivudine</description>
        </group>
        <group group_id="P2">
          <title>MK0518 200 mg b.i.d</title>
          <description>Cohort I-Monotherapy Phase
MK0518 200 mg b.i.d
Cohort II Combined-Combination Therapy Phase
MK0518 200 mg + tenofovir + lamivudine</description>
        </group>
        <group group_id="P3">
          <title>MK0518 400 mg b.i.d.</title>
          <description>Cohort I-Monotherapy Phase
MK0518 400 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 400 mg + tenofovir + lamivudine</description>
        </group>
        <group group_id="P4">
          <title>MK0518 600 mg b.i.d.</title>
          <description>Cohort I-Monotherapy Phase
MK0518 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 600 mg + tenofovir + lamivudine</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Cohort I-Monotherapy Phase
Placebo to MK0518 b.i.d.</description>
        </group>
        <group group_id="P6">
          <title>Efavirenz 600 mg q.h.s.</title>
          <description>Cohort II Combined-Combination Therapy Phase
efavirenz 600 mg every night at bedtime (q.h.s.)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Cohort I-Monotherapy Phase 10 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="0">participants only assigned Efavirenz 600 mg q.h.s in Cohort II Combined-Combination Therapy Phase</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7">7 Subjects Continued to Cohort II Combined-Combination Therapy Phase (48 Weeks)</participants>
                <participants group_id="P2" count="7">7 Subjects Continued to Cohort II Combined-Combination Therapy Phase (48 Weeks)</participants>
                <participants group_id="P3" count="6">6 Subjects Continued to Cohort II Combined-Combination Therapy Phase (48 Weeks)</participants>
                <participants group_id="P4" count="8">6 Subjects Continued to Cohort II Combined-Combination Therapy Phase (48 Weeks)</participants>
                <participants group_id="P5" count="7">4 Subjects Continued to Cohort II, as part of the Efavirenz 600 mg q.d. arm</participants>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Cohort I &amp; II-Combination Therapy Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41">7 subjects from the Monotherapy Phase and 34 new subjects</participants>
                <participants group_id="P2" count="40">7 subjects from the Monotherapy Phase and 33 new subjects</participants>
                <participants group_id="P3" count="41">6 subjects from the Monotherapy Phase and 35 new subjects</participants>
                <participants group_id="P4" count="40">8 subjects from the Monotherapy Phase and 32 new subjects</participants>
                <participants group_id="P5" count="0">participants only assigned Placebo in Cohort I-Monotherapy Phase.</participants>
                <participants group_id="P6" count="39">4 subjects from the Monotherapy Phase (Placebo)and 35 new subjects</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="40"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Never Treated</title>
              <participants_list>
                <participants group_id="P1" count="2">Randomised in Cohort II did not start Period</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1">Randomised in Cohort II did not start Period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="13"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Never Treated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Completed Base Study, Did Not Continue</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Laboratory Adverse Experience</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK0518 100 mg b.i.d.</title>
          <description>Cohort I-Monotherapy Phase (10 Days)
MK0518 100 mg twice daily (b.i.d.)
Cohort II Combined-Combination Therapy Phase (48 Weeks) MK0518 100 mg b.i.d</description>
        </group>
        <group group_id="B2">
          <title>MK0518 200 mg b.i.d</title>
          <description>Cohort I-Monotherapy Phase (10 Days)
MK0518 200 mg b.i.d
Cohort II Combined-Combination Therapy Phase (48 Weeks) MK0518 200 mg + tenofovir + lamivudine</description>
        </group>
        <group group_id="B3">
          <title>MK0518 400 mg b.i.d.</title>
          <description>Cohort I-Monotherapy Phase (10 Days)
MK0518 400 mg b.i.d.
Cohort II Combined-Combination Therapy Phase (48 Weeks) MK0518 400 mg + tenofovir + lamivudine</description>
        </group>
        <group group_id="B4">
          <title>MK0518 600 mg b.i.d.</title>
          <description>Cohort I-Monotherapy Phase (10 Days)
MK0518 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase (48 Weeks) MK0518 600 mg + tenofovir + lamivudine</description>
        </group>
        <group group_id="B5">
          <title>Placebo / Efavirenz 600 mg Once Daily (q.d.)</title>
          <description>Cohort I-Monotherapy Phase (10 Days)
Placebo to MK0518 b.i.d.
Cohort II Combined-Combination Therapy Phase (48 Weeks)
Efavirenz + Tenofovir + Lamivudine</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="41"/>
            <count group_id="B4" value="42"/>
            <count group_id="B5" value="42"/>
            <count group_id="B6" value="206"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Cohort I Participants: MK0518 100 mg b.i.d. (7); MK0518 200 mg b.i.d. (7); MK0518 400 mg b.i.d. (6); MK0518 600 mg b.i.d. (8); Placebo Cohort (7)
Cohort II Participants: MK0518 100 mg b.i.d. (33); MK0518 200 mg b.i.d. (33); MK0518 400 mg b.i.d. (35); MK0518 600 mg b.i.d. (34); Efavirenz 600 mg q.d. (34)
Cohort I &amp; II Participants Combined: MK0518 100 mg b.i.d. (39); MK0518 200 mg b.i.d. (40); MK0518 400 mg b.i.d. (41); MK0518 600 mg b.i.d. (40); Efavirenz 600 mg q.d. (38)</description>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Cohort I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46" lower_limit="31" upper_limit="68"/>
                    <measurement group_id="B2" value="37" lower_limit="22" upper_limit="57"/>
                    <measurement group_id="B3" value="41" lower_limit="25" upper_limit="55"/>
                    <measurement group_id="B4" value="39" lower_limit="30" upper_limit="49"/>
                    <measurement group_id="B5" value="36" lower_limit="21" upper_limit="51"/>
                    <measurement group_id="B6" value="40" lower_limit="21" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34" lower_limit="19" upper_limit="58"/>
                    <measurement group_id="B2" value="31" lower_limit="21" upper_limit="56"/>
                    <measurement group_id="B3" value="34" lower_limit="19" upper_limit="50"/>
                    <measurement group_id="B4" value="36" lower_limit="20" upper_limit="49"/>
                    <measurement group_id="B5" value="36" lower_limit="22" upper_limit="54"/>
                    <measurement group_id="B6" value="35" lower_limit="19" upper_limit="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort I &amp; II Combined</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" lower_limit="19" upper_limit="68"/>
                    <measurement group_id="B2" value="34" lower_limit="21" upper_limit="57"/>
                    <measurement group_id="B3" value="36" lower_limit="19" upper_limit="55"/>
                    <measurement group_id="B4" value="37" lower_limit="20" upper_limit="49"/>
                    <measurement group_id="B5" value="36" lower_limit="22" upper_limit="54"/>
                    <measurement group_id="B6" value="36" lower_limit="19" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female (Cohort I)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male (Cohort I)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female (Cohort II)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male (Cohort II)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never Treated Cohort II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White (Cohort I)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black (Cohort I)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian (Cohort I)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic (Cohort I)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White (Cohort II)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black (Cohort II)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian (Cohort II)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic (Cohort II)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other (Cohort II)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never Treated (Cohort II)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cluster of differentiation 4 (CD4) Cell Count</title>
          <description>Cohort I Participants: MK0518 100 mg b.i.d. (7); MK0518 200 mg b.i.d. (7); MK0518 400 mg b.i.d. (6); MK0518 600 mg b.i.d. (8); Placebo Cohort (7) Cohort II Participants: MK0518 100 mg b.i.d. (33); MK0518 200 mg b.i.d. (33); MK0518 400 mg b.i.d. (35); MK0518 600 mg b.i.d. (34); Efavirenz 600 mg q.d. (34) Cohort I &amp; II Participants Combined: MK0518 100 mg b.i.d. (39); MK0518 200 mg b.i.d. (40); MK0518 400 mg b.i.d. (41); MK0518 600 mg b.i.d. (40); Efavirenz 600 mg q.d. (38)</description>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Cohort I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="415" lower_limit="138" upper_limit="745"/>
                    <measurement group_id="B2" value="343" lower_limit="149" upper_limit="624"/>
                    <measurement group_id="B3" value="256" lower_limit="96" upper_limit="602"/>
                    <measurement group_id="B4" value="569" lower_limit="241" upper_limit="1034"/>
                    <measurement group_id="B5" value="343" lower_limit="115" upper_limit="599"/>
                    <measurement group_id="B6" value="394" lower_limit="96" upper_limit="1034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="293" lower_limit="76" upper_limit="736"/>
                    <measurement group_id="B2" value="292" lower_limit="70" upper_limit="723"/>
                    <measurement group_id="B3" value="348" lower_limit="95" upper_limit="1017"/>
                    <measurement group_id="B4" value="245" lower_limit="99" upper_limit="734"/>
                    <measurement group_id="B5" value="276" lower_limit="77" upper_limit="744"/>
                    <measurement group_id="B6" value="291" lower_limit="70" upper_limit="1017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort I and II Combined</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="272" lower_limit="76" upper_limit="758"/>
                    <measurement group_id="B2" value="277" lower_limit="70" upper_limit="723"/>
                    <measurement group_id="B3" value="293" lower_limit="95" upper_limit="1017"/>
                    <measurement group_id="B4" value="244" lower_limit="99" upper_limit="786"/>
                    <measurement group_id="B5" value="225" lower_limit="77" upper_limit="744"/>
                    <measurement group_id="B6" value="266" lower_limit="70" upper_limit="1017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Plasma Human Immunodeficiency Virus (HIV) Ribonucleic acid (RNA)</title>
          <description>Cohort I Participants: MK0518 100 mg b.i.d. (7); MK0518 200 mg b.i.d. (7); MK0518 400 mg b.i.d. (6); MK0518 600 mg b.i.d. (8); Placebo Cohort (7) Cohort II Participants: MK0518 100 mg b.i.d. (33); MK0518 200 mg b.i.d. (33); MK0518 400 mg b.i.d. (35); MK0518 600 mg b.i.d. (34); Efavirenz 600 mg q.d. (34) Cohort I &amp; II Participants Combined: MK0518 100 mg b.i.d. (39); MK0518 200 mg b.i.d. (40); MK0518 400 mg b.i.d. (41); MK0518 600 mg b.i.d. (40); Efavirenz 600 mg q.d. (38)</description>
          <units>copies/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Cohort I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44989" lower_limit="3890" upper_limit="225000"/>
                    <measurement group_id="B2" value="34143" lower_limit="5420" upper_limit="168000"/>
                    <measurement group_id="B3" value="37728" lower_limit="6850" upper_limit="152000"/>
                    <measurement group_id="B4" value="93911" lower_limit="17100" upper_limit="388000"/>
                    <measurement group_id="B5" value="58412" lower_limit="7630" upper_limit="456000"/>
                    <measurement group_id="B6" value="51496" lower_limit="3890" upper_limit="456000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65982" lower_limit="4200" upper_limit="750000"/>
                    <measurement group_id="B2" value="73646" lower_limit="7490" upper_limit="750000"/>
                    <measurement group_id="B3" value="47019" lower_limit="2440" upper_limit="499000"/>
                    <measurement group_id="B4" value="61929" lower_limit="3450" upper_limit="750000"/>
                    <measurement group_id="B5" value="76752" lower_limit="7500" upper_limit="675000"/>
                    <measurement group_id="B6" value="63965" lower_limit="2440" upper_limit="750000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort I and II Combined</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58206" lower_limit="4200" upper_limit="750000"/>
                    <measurement group_id="B2" value="64715" lower_limit="7490" upper_limit="750000"/>
                    <measurement group_id="B3" value="43083" lower_limit="2440" upper_limit="499000"/>
                    <measurement group_id="B4" value="57919" lower_limit="3450" upper_limit="750000"/>
                    <measurement group_id="B5" value="67554" lower_limit="3340" upper_limit="675000"/>
                    <measurement group_id="B6" value="57437" lower_limit="2440" upper_limit="750000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Plasma Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) on Day 10 (Cohort I)</title>
        <description>Mean change from baseline on Day 10 in plasma Human Immunodeficiency Virus (HIV) Ribonucleic acid (RNA) (copies/mL)</description>
        <time_frame>Baseline and Day 10</time_frame>
        <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 100 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 100 mg twice daily (b.i.d.)</description>
          </group>
          <group group_id="O2">
            <title>MK0518 200 mg b.i.d</title>
            <description>Cohort I-Monotherapy Phase
MK0518 200 mg b.i.d</description>
          </group>
          <group group_id="O3">
            <title>MK0518 400 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 400 mg b.i.d.</description>
          </group>
          <group group_id="O4">
            <title>MK0518 600 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 600 mg b.i.d.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Cohort I-Monotherapy Phase
Placebo to MK0518 b.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) on Day 10 (Cohort I)</title>
          <description>Mean change from baseline on Day 10 in plasma Human Immunodeficiency Virus (HIV) Ribonucleic acid (RNA) (copies/mL)</description>
          <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis.</population>
          <units>copies/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.93" lower_limit="-2.44" upper_limit="-1.42"/>
                    <measurement group_id="O2" value="-1.98" lower_limit="-2.49" upper_limit="-1.47"/>
                    <measurement group_id="O3" value="-1.66" lower_limit="-1.99" upper_limit="-1.34"/>
                    <measurement group_id="O4" value="-2.16" lower_limit="-2.55" upper_limit="-1.77"/>
                    <measurement group_id="O5" value="-0.17" lower_limit="-0.42" upper_limit="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Clinical Adverse Experiences (CAEs) and Number of Patients With Serious CAEs at Day 10 (Cohort I)</title>
        <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.
Serious CAEs are any AEs occurring at any dose that; Results
in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or
prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an
overdose.</description>
        <time_frame>10 days</time_frame>
        <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 100 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 100 mg twice daily (b.i.d.)</description>
          </group>
          <group group_id="O2">
            <title>MK0518 200 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 200 mg b.i.d</description>
          </group>
          <group group_id="O3">
            <title>MK0518 400 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 400 mg b.i.d.</description>
          </group>
          <group group_id="O4">
            <title>MK0518 600 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 600 mg b.i.d.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Cohort I-Monotherapy Phase
Placebo to MK0518 b.i.d.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Clinical Adverse Experiences (CAEs) and Number of Patients With Serious CAEs at Day 10 (Cohort I)</title>
          <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.
Serious CAEs are any AEs occurring at any dose that; Results
in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or
prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an
overdose.</description>
          <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 24 (Cohort II)</title>
        <time_frame>Week 24</time_frame>
        <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis.
All patients who took study medication and had HIV RNA tests performed were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 100 mg b.i.d.</title>
            <description>Cohort II Combined-Combination Therapy Phase
MK0518 100 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>MK0518 200 mg b.i.d</title>
            <description>Cohort II Combined-Combination Therapy Phase
MK0518 200 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O3">
            <title>MK0518 400 mg b.i.d.</title>
            <description>Cohort II Combined-Combination Therapy Phase
MK0518 400 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O4">
            <title>MK0518 600 mg b.i.d.</title>
            <description>Cohort II Combined-Combination Therapy Phase
MK0518 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O5">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II efavirenz + tenofovir +
lamivudine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 24 (Cohort II)</title>
          <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis.
All patients who took study medication and had HIV RNA tests performed were included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Clinical Adverse Experiences (CAEs)</title>
        <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.</description>
        <time_frame>48 weeks</time_frame>
        <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 100 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 100 mg twice daily (b.i.d.)
Cohort II Combined-Combination Therapy Phase
MK0518 100 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>MK0518 200 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 200 mg b.i.d
Cohort II Combined-Combination Therapy Phase
MK0518 200 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O3">
            <title>MK0518 400 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 400 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 400 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O4">
            <title>MK0518 600 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O5">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Clinical Adverse Experiences (CAEs)</title>
          <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.</description>
          <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 48</title>
        <time_frame>48 weeks</time_frame>
        <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 100 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 100 mg twice daily (b.i.d.)
Cohort II Combined-Combination Therapy Phase
MK0518 100 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>MK0518 200 mg b.i.d</title>
            <description>Cohort I-Monotherapy Phase
MK0518 200 mg b.i.d
Cohort II Combined-Combination Therapy Phase
MK0518 200 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O3">
            <title>MK0518 400 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 400 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 400 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O4">
            <title>MK0518 600 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O5">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 48</title>
          <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="40"/>
                    <measurement group_id="O4" value="36"/>
                    <measurement group_id="O5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Drug-related CAEs</title>
        <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs</description>
        <time_frame>48 weeks</time_frame>
        <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 100 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 100 mg twice daily (b.i.d.)
Cohort II Combined-Combination Therapy Phase
MK0518 100 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>MK0518 200 mg b.i.d</title>
            <description>Cohort I-Monotherapy Phase
MK0518 200 mg b.i.d
Cohort II Combined-Combination Therapy Phase
MK0518 200 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O3">
            <title>MK0518 400 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 400 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 400 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O4">
            <title>MK0518 600 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O5">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Drug-related CAEs</title>
          <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs</description>
          <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="22"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Serious Drug-related CAEs</title>
        <description>Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose. Drug-related are as assessed by an investigator who is a qualified physician according to his/her best clinical judgment.</description>
        <time_frame>48 Weeks</time_frame>
        <population>The analysis population is based upon the All Patients As Treated (APaT) approach</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 100 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 100 mg twice daily (b.i.d.)
Cohort II Combined-Combination Therapy Phase
MK0518 100 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>MK0518 200 mg b.i.d</title>
            <description>Cohort I-Monotherapy Phase
MK0518 200 mg b.i.d
Cohort II Combined-Combination Therapy Phase
MK0518 200 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O3">
            <title>MK0518 400 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 400 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 400 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O4">
            <title>MK0518 600 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O5">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious Drug-related CAEs</title>
          <description>Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose. Drug-related are as assessed by an investigator who is a qualified physician according to his/her best clinical judgment.</description>
          <population>The analysis population is based upon the All Patients As Treated (APaT) approach</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Serious drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Serious drug-related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients That Discontinued With CAEs</title>
        <time_frame>48 Weeks</time_frame>
        <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 100 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 100 mg twice daily (b.i.d.)
Cohort II Combined-Combination Therapy Phase
MK0518 100 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>MK0518 200 mg b.i.d</title>
            <description>Cohort I-Monotherapy Phase
MK0518 200 mg b.i.d
Cohort II Combined-Combination Therapy Phase
MK0518 200 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O3">
            <title>MK0518 400 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 400 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 400 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O4">
            <title>MK0518 600 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O5">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Discontinued With CAEs</title>
          <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued with CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Discontinue with CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Laboratory Adverse Experiences (LAEs)</title>
        <description>A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
        <time_frame>48 Weeks</time_frame>
        <population>The analysis population is based upon the All
Patients As Treated (APaT) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 100 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 100 mg twice daily (b.i.d.)
Cohort II Combined-Combination Therapy Phase
MK0518 100 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>MK0518 200 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 200 mg b.i.d
Cohort II Combined-Combination Therapy Phase
MK0518 200 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O3">
            <title>MK0518 400 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 400 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 400 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O4">
            <title>MK0518 600 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O5">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Laboratory Adverse Experiences (LAEs)</title>
          <description>A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
          <population>The analysis population is based upon the All
Patients As Treated (APaT) approach.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Serious LAEs</title>
        <description>Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
        <time_frame>48 Weeks</time_frame>
        <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 100 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 100 mg twice daily (b.i.d.)
Cohort II Combined-Combination Therapy Phase
MK0518 100 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>MK0518 200 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 200 mg b.i.d
Cohort II Combined-Combination Therapy Phase
MK0518 200 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O3">
            <title>MK0518 400 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 400 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 400 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O4">
            <title>MK0518 600 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O5">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious LAEs</title>
          <description>Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
          <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With serious LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without serious LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Drug-related LAEs</title>
        <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs</description>
        <time_frame>48 Weeks</time_frame>
        <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 100 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 100 mg twice daily (b.i.d.)
Cohort II Combined-Combination Therapy Phase
MK0518 100 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>MK0518 200 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 200 mg b.i.d
Cohort II Combined-Combination Therapy Phase
MK0518 200 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O3">
            <title>MK0518 400 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 400 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 400 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O4">
            <title>MK0518 600 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O5">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Drug-related LAEs</title>
          <description>Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) LAEs</description>
          <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With drug-related LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without drug-related LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="34"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients With Serious Drug-related LAEs</title>
        <description>Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
        <time_frame>48 Weeks</time_frame>
        <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 100 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 100 mg twice daily (b.i.d.)
Cohort II Combined-Combination Therapy Phase
MK0518 100 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>MK0518 200 mg b.i.d</title>
            <description>Cohort I-Monotherapy Phase
MK0518 200 mg b.i.d
Cohort II Combined-Combination Therapy Phase
MK0518 200 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O3">
            <title>MK0518 400 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 400 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 400 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O4">
            <title>MK0518 600 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O5">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious Drug-related LAEs</title>
          <description>Serious LAEs are any LAEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
          <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With serious LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without serious LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="40"/>
                    <measurement group_id="O5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Serious CAEs (Cohort I and II Combined)</title>
        <description>Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
        <time_frame>48 weeks</time_frame>
        <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 100 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 100 mg twice daily (b.i.d.)
Cohort II Combined-Combination Therapy Phase
MK0518 100 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>MK0518 200 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 200 mg b.i.d
Cohort II Combined-Combination Therapy Phase
MK0518 200 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O3">
            <title>MK0518 400 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 400 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 400 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O4">
            <title>MK0518 600 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O5">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious CAEs (Cohort I and II Combined)</title>
          <description>Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose</description>
          <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="38"/>
                    <measurement group_id="O5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With Serious CAEs and Non-serious CAEs at Week 144</title>
        <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product
An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
        <time_frame>144 Weeks</time_frame>
        <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 b.i.d.</title>
            <description>Cohort I-Monotherapy Phase (10 Days) MK0518 100, 200, 400, or 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase MK0518 100, 200, 400, or 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Serious CAEs and Non-serious CAEs at Week 144</title>
          <description>An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product
An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product</description>
          <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="153"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without serious CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV RNA Levels Below 50 Copies/mL at Week 24 (Cohort II)</title>
        <time_frame>Week 24</time_frame>
        <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 100 mg b.i.d.</title>
            <description>Cohort II Combined-Combination Therapy Phase
MK0518 100 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>MK0518 200 mg b.i.d</title>
            <description>Cohort II Combined-Combination Therapy Phase
MK0518 200 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O3">
            <title>MK0518 400 mg b.i.d.</title>
            <description>Cohort II Combined-Combination Therapy Phase
MK0518 400 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O4">
            <title>MK0518 600 mg b.i.d.</title>
            <description>Cohort II Combined-Combination Therapy Phase
MK0518 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O5">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II efavirenz + tenofovir +
lamivudine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV RNA Levels Below 50 Copies/mL at Week 24 (Cohort II)</title>
          <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="34"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="33"/>
                    <measurement group_id="O4" value="32"/>
                    <measurement group_id="O5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical Adverse Experiences (AEs)and Serious Adverse Experiences (SAEs)</title>
        <description>An AE was defined as any unfavorable &amp; unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to its use. Any worsening of a preexisting condition which was temporally associated with the use of the study drug, was also an AE.
A SAE was any AE that resulted in death, was life threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was cancer, or was an overdose.</description>
        <time_frame>Week 240</time_frame>
        <population>The analysis population was based upon the All Patients As Treated (APaT) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0518 b.i.d.</title>
            <description>Cohort I-Monotherapy Phase (10 Days) MK0518 100, 200, 400, or 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase (48 Weeks) MK0518 100, 200, 400, or 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>EVF Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical Adverse Experiences (AEs)and Serious Adverse Experiences (SAEs)</title>
          <description>An AE was defined as any unfavorable &amp; unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to its use. Any worsening of a preexisting condition which was temporally associated with the use of the study drug, was also an AE.
A SAE was any AE that resulted in death, was life threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was cancer, or was an overdose.</description>
          <population>The analysis population was based upon the All Patients As Treated (APaT) approach.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Adverse experiences</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious adverse experiences</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With HIV RNA (Human Immunodeficiency Virus Ribonucleic Acid) Levels Below 50 Copies/mL at Week 240</title>
        <description>HIV RNA levels were determined by AMPLICOR HIV-1 Monitor™ UltraSensitive Assay.</description>
        <time_frame>Week 240</time_frame>
        <population>Modified-Intention-to-Treat (MITT): participants were included in the treatment group to which they were randomized, regardless of adherence to the entry criteria, treatment actually received, and deviation from the protocol. Participants who were randomized but never dosed were not included in the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0518 b.i.d.</title>
            <description>Cohort I-Monotherapy Phase (10 Days) MK0518 100, 200, 400, or 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase (48 Weeks) MK0518 100, 200, 400, or 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV RNA (Human Immunodeficiency Virus Ribonucleic Acid) Levels Below 50 Copies/mL at Week 240</title>
          <description>HIV RNA levels were determined by AMPLICOR HIV-1 Monitor™ UltraSensitive Assay.</description>
          <population>Modified-Intention-to-Treat (MITT): participants were included in the treatment group to which they were randomized, regardless of adherence to the entry criteria, treatment actually received, and deviation from the protocol. Participants who were randomized but never dosed were not included in the analyses.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma HIV RNA at Week 24 (Cohort II)</title>
        <description>Mean change from baseline at Week 24 in plasma HIV RNA (copies/mL)</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 100 mg b.i.d.</title>
            <description>Cohort II Combined-Combination Therapy Phase
MK0518 100 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>MK0518 200 mg b.i.d</title>
            <description>Cohort II Combined-Combination Therapy Phase
MK0518 200 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O3">
            <title>MK0518 400 mg b.i.d.</title>
            <description>Cohort II Combined-Combination Therapy Phase
MK0518 400 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O4">
            <title>MK0518 600 mg b.i.d.</title>
            <description>Cohort II Combined-Combination Therapy Phase
MK0518 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O5">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II efavirenz + tenofovir +
lamivudine</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma HIV RNA at Week 24 (Cohort II)</title>
          <description>Mean change from baseline at Week 24 in plasma HIV RNA (copies/mL)</description>
          <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis.</population>
          <units>copies/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="35"/>
                <count group_id="O4" value="32"/>
                <count group_id="O5" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.39" lower_limit="-2.58" upper_limit="-2.21"/>
                    <measurement group_id="O2" value="-2.20" lower_limit="-2.55" upper_limit="-1.86"/>
                    <measurement group_id="O3" value="-2.33" lower_limit="-2.51" upper_limit="-2.14"/>
                    <measurement group_id="O4" value="-2.49" lower_limit="-2.72" upper_limit="-2.26"/>
                    <measurement group_id="O5" value="-2.44" lower_limit="-2.69" upper_limit="-2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Count at Week 24 (Cohort II)</title>
        <description>Mean change from baseline at Week 24 in CD4 Cell Count (cells/mm3)</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 100 mg b.i.d.</title>
            <description>Cohort II Combined-Combination Therapy Phase
MK0518 100 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>MK0518 200 mg b.i.d</title>
            <description>Cohort II Combined-Combination Therapy Phase
MK0518 200 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O3">
            <title>MK0518 400 mg b.i.d.</title>
            <description>Cohort II Combined-Combination Therapy Phase
MK0518 400 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O4">
            <title>MK0518 600 mg b.i.d.</title>
            <description>Cohort II Combined-Combination Therapy Phase
MK0518 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O5">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II efavirenz + tenofovir +
lamivudine</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cluster of Differentiation 4 (CD4) Cell Count at Week 24 (Cohort II)</title>
          <description>Mean change from baseline at Week 24 in CD4 Cell Count (cells/mm3)</description>
          <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis.</population>
          <units>cells/mm3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184" lower_limit="144.4" upper_limit="223.6"/>
                    <measurement group_id="O2" value="122" lower_limit="73.7" upper_limit="169.2"/>
                    <measurement group_id="O3" value="147" lower_limit="112.3" upper_limit="182.6"/>
                    <measurement group_id="O4" value="134" lower_limit="100.8" upper_limit="166.3"/>
                    <measurement group_id="O5" value="101" lower_limit="59.6" upper_limit="142.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With HIV RNA Level Below 50 Copies/mL and HIV RNA Level Below 400 Copies/mL at Week 96</title>
        <time_frame>96 Weeks</time_frame>
        <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis. All patients switched to MK0518 400 mg b.i.d post 48 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 b.i.d.</title>
            <description>Cohort I-Monotherapy Phase (10 Days) MK0518 100, 200, 400, or 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase MK0518 100, 200, 400, or 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With HIV RNA Level Below 50 Copies/mL and HIV RNA Level Below 400 Copies/mL at Week 96</title>
          <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis. All patients switched to MK0518 400 mg b.i.d post 48 weeks.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HIV RNA &lt;50 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HIV RNA &lt;400 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma HIV RNA at Week 96</title>
        <time_frame>Baseline and Week 96</time_frame>
        <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis. All patients switched to MK0518 400 mg b.i.d post 48 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 b.i.d.</title>
            <description>Cohort I-Monotherapy Phase (10 Days) MK0518 100, 200, 400, or 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase MK0518 100, 200, 400, or 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma HIV RNA at Week 96</title>
          <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis. All patients switched to MK0518 400 mg b.i.d post 48 weeks.</population>
          <units>copies/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="144"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.30" lower_limit="-2.42" upper_limit="-2.19"/>
                    <measurement group_id="O2" value="-2.28" lower_limit="-2.57" upper_limit="-2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 Cell Count at Week 96</title>
        <time_frame>Baseline and Week 96</time_frame>
        <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis. All patients switched to MK0518 400 mg b.i.d post 48 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 b.i.d.</title>
            <description>Cohort I-Monotherapy Phase (10 Days) MK0518 100, 200, 400, or 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase MK0518 100, 200, 400, or 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 Cell Count at Week 96</title>
          <population>The analysis population is based upon the modified intent to treat (MITT) approach, where patients are included in the treatment group to which they were randomized. Patients who were randomized but never dosed are not included in the analysis. All patients switched to MK0518 400 mg b.i.d post 48 weeks.</population>
          <units>cells/mm3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="221.2" lower_limit="196.8" upper_limit="245.7"/>
                    <measurement group_id="O2" value="232.4" lower_limit="179.6" upper_limit="285.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 240</title>
        <description>HIV RNA levels were determined by AMPLICOR HIV-1 Monitor™ Standard Assay.</description>
        <time_frame>Week 240</time_frame>
        <population>Modified-Intention-to-Treat (MITT): participants were included in the treatment group to which they were randomized, regardless of adherence to the entry criteria, treatment actually received, and deviation from the protocol. Participants who were randomized but never dosed were not included in the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0518 b.i.d.</title>
            <description>Cohort I-Monotherapy Phase (10 Days) MK0518 100, 200, 400, or 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase (48 Weeks) MK0518 100, 200, 400, or 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>EVF Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With HIV RNA Levels Below 400 Copies/mL at Week 240</title>
          <description>HIV RNA levels were determined by AMPLICOR HIV-1 Monitor™ Standard Assay.</description>
          <population>Modified-Intention-to-Treat (MITT): participants were included in the treatment group to which they were randomized, regardless of adherence to the entry criteria, treatment actually received, and deviation from the protocol. Participants who were randomized but never dosed were not included in the analyses.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma HIV RNA at Week 240</title>
        <description>HIV RNA levels were determined by AMPLICOR HIV-1 Monitor™ Standard Assay.</description>
        <time_frame>Baseline and Week 240</time_frame>
        <population>Modified-Intention-to-Treat (MITT): participants were included in the treatment group to which they were randomized, regardless of adherence to the entry criteria, treatment actually received, and deviation from the protocol. Participants who were randomized but never dosed were not included in the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0518 b.i.d.</title>
            <description>Cohort I-Monotherapy Phase (10 Days) MK0518 100, 200, 400, or 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase (48 Weeks) MK0518 100, 200, 400, or 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>EVF Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma HIV RNA at Week 240</title>
          <description>HIV RNA levels were determined by AMPLICOR HIV-1 Monitor™ Standard Assay.</description>
          <population>Modified-Intention-to-Treat (MITT): participants were included in the treatment group to which they were randomized, regardless of adherence to the entry criteria, treatment actually received, and deviation from the protocol. Participants who were randomized but never dosed were not included in the analyses.</population>
          <units>Log10Copies/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.29" lower_limit="-2.43" upper_limit="-2.15"/>
                    <measurement group_id="O2" value="-2.07" lower_limit="-2.45" upper_limit="-1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4 (T-helper) Cell Count at Week 240</title>
        <description>Change in number of CD4 cells/mm^3 from baseline to Week 240.</description>
        <time_frame>Baseline and Week 240</time_frame>
        <population>Modified-Intention-to-Treat (MITT): participants were included in the treatment group to which they were randomized, regardless of adherence to the entry criteria, treatment actually received, and deviation from the protocol. Participants who were randomized but never dosed were not included in the analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>MK-0518 b.i.d.</title>
            <description>Cohort I-Monotherapy Phase (10 Days) MK0518 100, 200, 400, or 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase (48 Weeks) MK0518 100, 200, 400, or 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>EVF Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4 (T-helper) Cell Count at Week 240</title>
          <description>Change in number of CD4 cells/mm^3 from baseline to Week 240.</description>
          <population>Modified-Intention-to-Treat (MITT): participants were included in the treatment group to which they were randomized, regardless of adherence to the entry criteria, treatment actually received, and deviation from the protocol. Participants who were randomized but never dosed were not included in the analyses.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301.7" lower_limit="268.0" upper_limit="335.5"/>
                    <measurement group_id="O2" value="275.6" lower_limit="209.9" upper_limit="341.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Patients That Discontinued With LAEs</title>
        <time_frame>48 Weeks</time_frame>
        <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
        <group_list>
          <group group_id="O1">
            <title>MK0518 100 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 100 mg twice daily (b.i.d.)
Cohort II Combined-Combination Therapy Phase
MK0518 100 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O2">
            <title>MK0518 200 mg b.i.d</title>
            <description>Cohort I-Monotherapy Phase
MK0518 200 mg b.i.d
Cohort II Combined-Combination Therapy Phase
MK0518 200 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O3">
            <title>MK0518 400 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 400 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 400 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O4">
            <title>MK0518 600 mg b.i.d.</title>
            <description>Cohort I-Monotherapy Phase
MK0518 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase
MK0518 600 mg + tenofovir + lamivudine</description>
          </group>
          <group group_id="O5">
            <title>EFV Combo Therapy</title>
            <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients That Discontinued With LAEs</title>
          <population>The analysis population is based upon the All Patients As Treated (APaT) approach.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Discontinued With LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Did Not Discontinue With LAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="39"/>
                    <measurement group_id="O5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MK-0518 b.i.d.</title>
          <description>Cohort I-Monotherapy Phase (10 Days) MK0518 100, 200, 400, or 600 mg b.i.d.
Cohort II Combined-Combination Therapy Phase MK0518 100, 200, 400, or 600 mg + tenofovir + lamivudine</description>
        </group>
        <group group_id="E2">
          <title>Efavirenz</title>
          <description>EFV Combo Therapy Phase - Cohort II
efavirenz 600 mg daily at bedtime (qhs) + tenofovir + lamivudine
This arm included participants from Cohort I who were randomized to placebo.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal vein occlusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Amoebic dysentery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Burns third degree</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma AIDS related</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia facial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="147" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="67" subjects_affected="42" subjects_at_risk="160"/>
                <counts group_id="E2" events="19" subjects_affected="10" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="40" subjects_affected="35" subjects_at_risk="160"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="160"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="17" subjects_affected="13" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="31" subjects_affected="23" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="57" subjects_affected="30" subjects_at_risk="160"/>
                <counts group_id="E2" events="13" subjects_affected="8" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="160"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="16" subjects_at_risk="160"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="74" subjects_affected="39" subjects_at_risk="160"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="29" subjects_affected="13" subjects_at_risk="160"/>
                <counts group_id="E2" events="10" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="160"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="160"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Overweight</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="14" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="23" subjects_affected="22" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="33" subjects_affected="29" subjects_at_risk="160"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="56" subjects_affected="33" subjects_at_risk="160"/>
                <counts group_id="E2" events="31" subjects_affected="16" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="160"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="23" subjects_affected="20" subjects_at_risk="160"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="160"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="160"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="38"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="160"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="38"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vice President, Late Stage Development Group Leader</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

